ImaginAb

ImaginAb is a clinical-stage global biotechnology company focused on developing next-generation imaging agents and radiopharmaceutical therapy (RPT) products through its proprietary minibody and cys-diabody platforms. The company's lead candidate, 89Zr crefmirlimab berdoxam (CD8 ImmunoPET), is an 89Zr-labeled minibody designed to bind to the CD8 receptor on human T cells for quantitative, non-invasive PET imaging.

CD8 ImmunoPET is currently in Phase II clinical trials and is being researched to determine its potential in assessing a patient's immune status, measuring the efficacy of immunotherapies, and predicting patient outcomes. ImaginAb has licensed CD8 ImmunoPET to numerous pharmaceutical and biotech companies for use in their immunotherapy clinical trials, primarily in oncology.

In addition to its imaging agent, ImaginAb is expanding its pipeline to include the development of RPT agents based on its minibody and cys-dibody platforms. The company has identified potential clinical candidates for two cancer targets and is initiating IND-enabling studies.

ImaginAb has established a global network for manufacturing and distributing CD8 ImmunoPET, with agreements in place for commercial manufacturing and distribution in various regions, including the US, Turkey, South Korea, and other Asian countries. In May 2022, ImaginAb signed an exclusive license agreement with DongCheng Pharmaceutical Group to utilize and commercialize CD8 ImmunoPET in pharma and biotech clinical trials in China.

In October 2022, ImaginAb announced the acquisition of a radiopharmaceutical therapy company, further expanding its portfolio into the RPT field.